ANCA Vasculitis is an autoimmune disease that results in inflammation of small blood vessels due to the presence of anti-neutrophil cytoplasmic antibodies (ANCAs). ANCAs target neutrophils, a specific type of white blood cell, causing them to attack the body's small blood vessels. This leads to the development of vasculitis, characterized by swelling and inflammation of the blood vessels.
The market for drugs treating global ANCA Vasculitis is projected to have a value of approximately US$ 463.82 million in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 5.5% from 2022 to 2030.
Approval of ANCA vasculitis drugs by regulatory bodies is predicted to fuel the growth of the market. Key market players are dedicated to obtaining approvals for drugs treating ANCA vasculitis, which will drive market expansion. Additionally, increased research and development efforts by these players to create ANCA vasculitis drugs are expected to contribute to market growth in the foreseeable future.
Leading Companies in the ANCA Vasculitis Drug Industry:
ChemoCentryx, Inc.
ChemoCentryx, Inc. was established in 1996 and is headquartered in San Carlos, California, U.S. It operates in over 24 countries and is engaged in various industries, including biotechnology, healthcare, and medical devices. In 2021, ChemoCentryx, Inc., announced that the USFDA had approved tavneos (avacopan), an orally administered selective complement 5a receptor inhibitor, as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (also known as ANCA-associated vasculitis or ANCA vasculitis).
InflaRx GmbH
InflaRx GmbH was established in 2007 and is headquartered in Jena, Germany. It is engaged in various industries, including healthcare, medical, pharmaceuticals, and therapeutics. In 2021, InflaRx N.V. announced positive data from the European Phase II IXCHANGE study of vilobelimab, a first-in-class anti-C5a antibody, in patients with ANCA-associated vasculitis (AAV).